Interacciones de Lorlatinib

CYP3A4 Inducers: Avoid concomitant strong CYP3A4 inducers during YONSA treatment. (etiqueta de Abiraterona, Interacciones medicamentosas)

• CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (etiqueta de Acalabrutinib, Interacciones medicamentosas)

CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (etiqueta de Alpelisib, Interacciones medicamentosas)

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (etiqueta de Lorlatinib, Interacciones medicamentosas)

• Simultaneous use of combined P-gp and strong CYP3A4 inducers reduces blood levels of apixaban: Avoid concomitant use. (etiqueta de Apixabán, Interacciones medicamentosas)

Drug Interactions : Use with strong cytochrome P450 enzyme inducers (e.g., rifampin, phenobarbital, carbamazepine, phenytoin) is not recommended because loss of efficacy may occur ( 5.5 , 7.1 ) (etiqueta de Apremilast, Advertencias y precauciones)

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (etiqueta de Lorlatinib, Interacciones medicamentosas)

CYP3A4 Inducers : Avoid concomitant use for greater than 14 days ( 7.1 ) (etiqueta de Aripiprazol, Interacciones medicamentosas)

Effect of Other Drugs on LORBRENA Strong CYP3A Inducers LORBRENA is contraindicated in patients taking strong CYP3A inducers [see Contraindication (4) ] . (etiqueta de Lorlatinib, Interacciones medicamentosas)

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (etiqueta de Lorlatinib, Interacciones medicamentosas)

Concomitant administration of BIXLENVO is contraindicated with: dofetilide due to the potential for increased dofetilide plasma concentrations and associated serious and/or life-threatening events. strong CYP3A inducers due to decreased plasma concentrations of BIC and LEN, which may result in the loss of therapeutic effect and development of resistance to BIXLENVO. (etiqueta de Bictegravir, emtricitabina y tenofovir alafenamida, Contraindicaciones)

Strong CYP3A4 Inducers: Avoid concomitant use. (etiqueta de Bortezomib, Interacciones medicamentosas)

Effect of Other Drugs on LORBRENA Strong CYP3A Inducers LORBRENA is contraindicated in patients taking strong CYP3A inducers [see Contraindication (4) ] . (etiqueta de Lorlatinib, Interacciones medicamentosas)

• Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (etiqueta de Buprenorfina, Interacciones medicamentosas)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (etiqueta de Butalbital, ácido acetilsalicílico, cafeína y codeína, Advertencia en recuadro)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (etiqueta de Butalbital, paracetamol, cafeína y codeína, Advertencia en recuadro)

Avoid chronic co-administration of strong CYP3A4 inducers (e.g., phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, St. (etiqueta de Cabozantinib, Interacciones medicamentosas)

Effect of Other Drugs on LORBRENA Strong CYP3A Inducers LORBRENA is contraindicated in patients taking strong CYP3A inducers [see Contraindication (4) ] . (etiqueta de Lorlatinib, Interacciones medicamentosas)

Intervention: Concomitant use of VRAYLAR with a CYP3A4 inducer is not recommended [see Dosage and Administration ( 2.1 , 2.6 ) ] . (etiqueta de Cariprazina, Interacciones medicamentosas)

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (etiqueta de Lorlatinib, Interacciones medicamentosas)

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (etiqueta de Lorlatinib, Interacciones medicamentosas)

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (etiqueta de Lorlatinib, Interacciones medicamentosas)

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (etiqueta de Lorlatinib, Interacciones medicamentosas)

Effect of Other Drugs on LORBRENA Strong CYP3A Inducers LORBRENA is contraindicated in patients taking strong CYP3A inducers [see Contraindication (4) ] . (etiqueta de Lorlatinib, Interacciones medicamentosas)

• Concomitant use of Strong CYP3A4 Inducers is not recommended. (etiqueta de Clozapina, Interacciones medicamentosas)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (etiqueta de Codeína, Advertencia en recuadro)

P-gp inducers: Avoid coadministration with PRADAXA ( 5.5 ) (etiqueta de Dabigatrán, Interacciones medicamentosas)

Moderate or Strong CYP3A4 inducers: Avoid concomitant use. (etiqueta de Daridorexant, Interacciones medicamentosas)

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (etiqueta de Lorlatinib, Interacciones medicamentosas)

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (etiqueta de Lorlatinib, Interacciones medicamentosas)

If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (etiqueta de Dasatinib, Interacciones medicamentosas)

Effect of Other Drugs on LORBRENA Strong CYP3A Inducers LORBRENA is contraindicated in patients taking strong CYP3A inducers [see Contraindication (4) ] . (etiqueta de Lorlatinib, Interacciones medicamentosas)

Avoid use of moderate or strong CYP3A4 inducers with EMFLAZA, as they may reduce efficacy ( 7.1 ) (etiqueta de Deflazacort, Interacciones medicamentosas)

Effect of Other Drugs on LORBRENA Strong CYP3A Inducers LORBRENA is contraindicated in patients taking strong CYP3A inducers [see Contraindication (4) ] . (etiqueta de Lorlatinib, Interacciones medicamentosas)

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (etiqueta de Lorlatinib, Interacciones medicamentosas)

PIFELTRO is contraindicated when co-administered with drugs that are strong cytochrome P450 (CYP)3A enzyme inducers as significant decreases in doravirine plasma concentrations may occur, which may decrease the effectiveness of PIFELTRO [see Warnings and Precautions (5.2) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ] . (etiqueta de Doravirina, Contraindicaciones)

• Avoid concomitant use of doxorubicin hydrochloride with inhibitors and inducers of CYP3A4, CYP2D6, and/or P-gp ( 7.1 ) (etiqueta de Doxorubicina, Interacciones medicamentosas)

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (etiqueta de Lorlatinib, Interacciones medicamentosas)

P-gp Inducers Avoid the concomitant use of SAVAYSA with rifampin [see Clinical Pharmacology (12.3) ] . (etiqueta de Edoxabán, Interacciones medicamentosas)

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (etiqueta de Lorlatinib, Interacciones medicamentosas)

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (etiqueta de Lorlatinib, Interacciones medicamentosas)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (etiqueta de Elexacaftor, tezacaftor e ivacaftor, Advertencias y precauciones)

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (etiqueta de Lorlatinib, Interacciones medicamentosas)

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (etiqueta de Lorlatinib, Interacciones medicamentosas)

Effect of Other Drugs on LORBRENA Strong CYP3A Inducers LORBRENA is contraindicated in patients taking strong CYP3A inducers [see Contraindication (4) ] . (etiqueta de Lorlatinib, Interacciones medicamentosas)

Effect of Other Drugs on LORBRENA Strong CYP3A Inducers LORBRENA is contraindicated in patients taking strong CYP3A inducers [see Contraindication (4) ] . (etiqueta de Lorlatinib, Interacciones medicamentosas)

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (etiqueta de Lorlatinib, Interacciones medicamentosas)

Effect of Other Drugs on LORBRENA Strong CYP3A Inducers LORBRENA is contraindicated in patients taking strong CYP3A inducers [see Contraindication (4) ] . (etiqueta de Lorlatinib, Interacciones medicamentosas)

Effect of Other Drugs on LORBRENA Strong CYP3A Inducers LORBRENA is contraindicated in patients taking strong CYP3A inducers [see Contraindication (4) ] . (etiqueta de Lorlatinib, Interacciones medicamentosas)

• Concomitant use with CYP3A4 inhibitors (or discontinuation of CYP3A4 inducers) can result in a fatal overdose of fentanyl. (etiqueta de Fentanilo, Advertencia en recuadro)

Effect of Other Drugs on LORBRENA Strong CYP3A Inducers LORBRENA is contraindicated in patients taking strong CYP3A inducers [see Contraindication (4) ] . (etiqueta de Lorlatinib, Interacciones medicamentosas)

Preventing or Managing DI The concomitant use of ADDYI with CYP3A4 inducers is not recommended. (etiqueta de Flibanserina, Interacciones medicamentosas)

• Fluconazole : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (etiqueta de Lorlatinib, Interacciones medicamentosas)

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (etiqueta de Lorlatinib, Interacciones medicamentosas)

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (etiqueta de Lorlatinib, Interacciones medicamentosas)

Effect of Other Drugs on LORBRENA Strong CYP3A Inducers LORBRENA is contraindicated in patients taking strong CYP3A inducers [see Contraindication (4) ] . (etiqueta de Lorlatinib, Interacciones medicamentosas)

Effect of Other Drugs on LORBRENA Strong CYP3A Inducers LORBRENA is contraindicated in patients taking strong CYP3A inducers [see Contraindication (4) ] . (etiqueta de Lorlatinib, Interacciones medicamentosas)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentration. (etiqueta de Hidrocodona, Advertencia en recuadro)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentration. (etiqueta de Hidrocodona e ibuprofeno, Advertencia en recuadro)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentration. (etiqueta de Hidrocodona y clorfenamina, Advertencia en recuadro)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentration. (etiqueta de Hidrocodona y homatropina, Advertencia en recuadro)

In addition, discontinuation of a concomitantly used Cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentrations. (etiqueta de Hidrocodona y paracetamol, Advertencia en recuadro)

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (etiqueta de Lorlatinib, Interacciones medicamentosas)

• Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (etiqueta de Irinotecán, Interacciones medicamentosas)

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (etiqueta de Lorlatinib, Interacciones medicamentosas)

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (etiqueta de Lorlatinib, Interacciones medicamentosas)

Avoid concomitant use of CYP3A4 inducers when using Corlanor. (etiqueta de Ivabradina, Interacciones medicamentosas)

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (etiqueta de Lorlatinib, Interacciones medicamentosas)

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (etiqueta de Lorlatinib, Interacciones medicamentosas)

Avoid strong CYP3A4 inducers. (etiqueta de Lapatinib, Interacciones medicamentosas)

Strong CYP3A4 Inducers: Avoid coadministration of strong CYP3A4 inducers with VITRAKVI. (etiqueta de Larotrectinib, Interacciones medicamentosas)

Use of ledipasvir and sofosbuvir with P-gp inducers is not recommended. (etiqueta de Ledipasvir y sofosbuvir, Interacciones medicamentosas)

Strong or moderate CYP3A inducers: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (etiqueta de Lorlatinib, Interacciones medicamentosas)

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (etiqueta de Lorlatinib, Interacciones medicamentosas)

CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (etiqueta de Lumateperona, Interacciones medicamentosas)

Strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. (etiqueta de Lurasidona, Contraindicaciones)

Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (etiqueta de Lorlatinib, Interacciones medicamentosas)

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (etiqueta de Lorlatinib, Interacciones medicamentosas)

Effect of Other Drugs on LORBRENA Strong CYP3A Inducers LORBRENA is contraindicated in patients taking strong CYP3A inducers [see Contraindication (4) ] . (etiqueta de Lorlatinib, Interacciones medicamentosas)

Effect of Other Drugs on LORBRENA Strong CYP3A Inducers LORBRENA is contraindicated in patients taking strong CYP3A inducers [see Contraindication (4) ] . (etiqueta de Lorlatinib, Interacciones medicamentosas)

Effect of Other Drugs on LORBRENA Strong CYP3A Inducers LORBRENA is contraindicated in patients taking strong CYP3A inducers [see Contraindication (4) ] . (etiqueta de Lorlatinib, Interacciones medicamentosas)

Effect of Other Drugs on LORBRENA Strong CYP3A Inducers LORBRENA is contraindicated in patients taking strong CYP3A inducers [see Contraindication (4) ] . (etiqueta de Lorlatinib, Interacciones medicamentosas)

John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (etiqueta de Naldemedina, Interacciones medicamentosas)

Strong CYP3A4 inducers (e.g., rifampin) : Decreased concentrations of naloxegol; concomitant use is not recommended. (etiqueta de Naloxegol, Interacciones medicamentosas)

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (etiqueta de Lorlatinib, Interacciones medicamentosas)

Effect of Other Drugs on LORBRENA Strong CYP3A Inducers LORBRENA is contraindicated in patients taking strong CYP3A inducers [see Contraindication (4) ] . (etiqueta de Lorlatinib, Interacciones medicamentosas)

John’s Wort reduce the bioavailability and efficacy of nifedipine; therefore nifedipine should not be used in combination with strong CYP3A inducers such as rifampin (See CONTRAINDICATIONS ). (etiqueta de Nifedipino, Interacciones medicamentosas)

Strong CYP3A Inducers: Avoid concomitant use with CAVHANZA. (etiqueta de Nilotinib, Interacciones medicamentosas)

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (etiqueta de Lorlatinib, Interacciones medicamentosas)

Counsel patients to use a back-up method or alternative method of contraception when enzyme inducers are used with COCs ( 7.1 ) -- - ---------- ------ USE IN SPECIFIC POPULATIONS---- -- -- --------- ---- Lactation: Not recommended; Lo Loestrin Fe can decrease milk production ( 8.2 ) (etiqueta de Noretisterona y etinilestradiol, Interacciones medicamentosas)

If a CYP3A4 inducer is discontinued, consider OLINVYK dosage reduction and monitor for signs of respiratory depression. (etiqueta de Oliceridina, Interacciones medicamentosas)

Effect of Other Drugs on LORBRENA Strong CYP3A Inducers LORBRENA is contraindicated in patients taking strong CYP3A inducers [see Contraindication (4) ] . (etiqueta de Lorlatinib, Interacciones medicamentosas)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in oxycodone plasma concentration. (etiqueta de Oxicodona, Advertencia en recuadro)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in oxycodone plasma concentration. (etiqueta de Oxicodona y paracetamol, Advertencia en recuadro)

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (etiqueta de Lorlatinib, Interacciones medicamentosas)

Strong CYP3A4 and P-glycoprotein (P-gp) inducers : Avoid using a strong inducer of CYP3A4 and/or P-gp during a dosing interval for ERZOFRI. (etiqueta de Paliperidona, Interacciones medicamentosas)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (etiqueta de Paracetamol y codeína, Advertencia en recuadro)

VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etiqueta de Pazopanib, Interacciones medicamentosas)

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (etiqueta de Lorlatinib, Interacciones medicamentosas)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in meperidine plasma concentration. (etiqueta de Petidina (meperidina), Advertencia en recuadro)

Strong or Moderate CYP3A4 Inducers: Avoid concomitant use of NUPLAZID. (etiqueta de Pimavanserina, Interacciones medicamentosas)

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (etiqueta de Lorlatinib, Interacciones medicamentosas)

• Patients taking strong Cytochrome P450 3A enzyme (CYP3A) inducers, such as rifampin, [see Warnings and Precautions ( 5.6 ) and Drug Interactions ( 7.1 , 7.2 )] . (etiqueta de Praziquantel, Contraindicaciones)

Effect of Other Drugs on LORBRENA Strong CYP3A Inducers LORBRENA is contraindicated in patients taking strong CYP3A inducers [see Contraindication (4) ] . (etiqueta de Lorlatinib, Interacciones medicamentosas)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex, requiring careful consideration of the effects on the parent drug, codeine, and the active metabolite, morphine. (etiqueta de Prometazina y codeína, Advertencia en recuadro)

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (etiqueta de Lorlatinib, Interacciones medicamentosas)

Effect of Other Drugs on LORBRENA Strong CYP3A Inducers LORBRENA is contraindicated in patients taking strong CYP3A inducers [see Contraindication (4) ] . (etiqueta de Lorlatinib, Interacciones medicamentosas)

Effect of Other Drugs on LORBRENA Strong CYP3A Inducers LORBRENA is contraindicated in patients taking strong CYP3A inducers [see Contraindication (4) ] . (etiqueta de Lorlatinib, Interacciones medicamentosas)

Effect of Other Drugs on LORBRENA Strong CYP3A Inducers LORBRENA is contraindicated in patients taking strong CYP3A inducers [see Contraindication (4) ] . (etiqueta de Lorlatinib, Interacciones medicamentosas)

• Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (etiqueta de Rimegepant, Interacciones medicamentosas)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (etiqueta de Ritlecitinib, Interacciones medicamentosas)

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (etiqueta de Lorlatinib, Interacciones medicamentosas)

Avoid concomitant use of XARELTO with drugs that are known combined P-gp and strong CYP3A inducers [see Drug Interactions (7.3) ] . (etiqueta de Rivaroxabán, Advertencias y precauciones)

• Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (etiqueta de Roflumilast, Advertencias y precauciones)

Intervention: Avoid the use of VARUBI in patients who require chronic administration of strong CYP3A4 inducers. (etiqueta de Rolapitant, Interacciones medicamentosas)

• Avoid use with rifampin and strong CYP3A4 inducers ( 7.3 ). (etiqueta de Romidepsina, Interacciones medicamentosas)

Interaction with Strong Inhibitors and Inducers of CYP3A4 and/or P-gp Avoid concomitant use of sirolimus with strong inhibitors of CYP3A4 and/or P-gp (such as ketoconazole, voriconazole, itraconazole, erythromycin, telithromycin, or clarithromycin) or strong inducers of CYP3A4 and/or P-gp (such as rifampin or rifabutin) [ see Drug Interactions (7.2) ]. (etiqueta de Sirolimus, Advertencias y precauciones)

Use of VOSEVI with P-gp inducers and/or moderate to strong CYP inducers is not recommended. (etiqueta de Sofosbuvir y velpatasvir, Interacciones medicamentosas)

• Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (etiqueta de Sorafenib, Interacciones medicamentosas)

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (etiqueta de Lorlatinib, Interacciones medicamentosas)

Effect of Other Drugs on LORBRENA Strong CYP3A Inducers LORBRENA is contraindicated in patients taking strong CYP3A inducers [see Contraindication (4) ] . (etiqueta de Lorlatinib, Interacciones medicamentosas)

Inducers of CYP3A4 Strong CYP3A4 inducers should not be used with tamoxifen. (etiqueta de Tamoxifeno, Interacciones medicamentosas)

Strong CYP3A4 inducers (e.g., rifampin): Avoid use of HETLIOZ in combination with rifampin or other CYP3A4 inducers, because of decreased exposure ( 7.2 , 12.3 ) (etiqueta de Tasimelteón, Interacciones medicamentosas)

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (etiqueta de Lorlatinib, Interacciones medicamentosas)

Avoid co-administration of strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, ritonavir) and strong CYP3A4 inducers (e.g., rifampin, phenytoin) with TEPADINA due to the potential effects on efficacy and toxicity [see Clinical Pharmacology ( 12.3 ) ] . (etiqueta de Tiotepa, Interacciones medicamentosas)

Avoid concomitant use of SAMSCA with strong CYP3A inducers. (etiqueta de Tolvaptán, Interacciones medicamentosas)

Effect of Other Drugs on LORBRENA Strong CYP3A Inducers LORBRENA is contraindicated in patients taking strong CYP3A inducers [see Contraindication (4) ] . (etiqueta de Lorlatinib, Interacciones medicamentosas)

Coadministration with a strong CYP3A4 inducer may result in a relevant decrease in FARESTON exposure and should be avoided. (etiqueta de Toremifeno, Interacciones medicamentosas)

CYP3A inducers: Avoid concomitant strong CYP3A inducers ( 7.1 ) (etiqueta de Trabectedina, Interacciones medicamentosas)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with tramadol are complex. (etiqueta de Tramadol, Advertencia en recuadro)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with tramadol are complex. (etiqueta de Tramadol y paracetamol, Advertencia en recuadro)

Avoid concomitant use with strong CYP3A inducers if possible. (etiqueta de Tretinoína, Interacciones medicamentosas)

Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (etiqueta de Ubrogepant, Interacciones medicamentosas)

Ella should not be administered with CYP3A4 inducers [see Drug interactions (7.1) and Clinical Pharmacology (12.3) ] . (etiqueta de Ulipristal, Advertencias y precauciones)

Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (etiqueta de Upadacitinib, Interacciones medicamentosas)

Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. (etiqueta de Valbenazina, Interacciones medicamentosas)

Strong CYP3A Inducers : Avoid concomitant use with strong CYP3A inducers. (etiqueta de Vepdegestrant, Interacciones medicamentosas)

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (etiqueta de Lorlatinib, Interacciones medicamentosas)

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (etiqueta de Lorlatinib, Interacciones medicamentosas)

John's wort, a CYP3A4 inducer, in combination with zolpidem may decrease blood levels of zolpidem and is not recommended. (etiqueta de Zolpidem, Interacciones medicamentosas)

Hepatic enzyme-inducing drugs (e.g., phenytoin, carbamazepine, phenobarbital, primidone, rifampin) can increase valproate clearance, while enzyme inhibitors (e.g., felbamate) can decrease valproate clearance. (etiqueta de Ácido valproico, Interacciones medicamentosas)

P-gp Inducers : Co-administration of chronic P-gp inducers orally can decrease afatinib exposure. (etiqueta de Afatinib, Interacciones medicamentosas)

• Use with CYP3A Inducers: Increase the risk of reduced efficacy of alprazolam. (etiqueta de Alprazolam, Interacciones medicamentosas)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (etiqueta de Amlodipino, Interacciones medicamentosas)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (etiqueta de Amlodipino y atorvastatina, Interacciones medicamentosas)

Blood pressure should be monitored when amlodipine is coadministered with CYP3A4 inducers (e.g. rifampicin, St. (etiqueta de Amlodipino y benazepril, Interacciones medicamentosas)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (etiqueta de Amlodipino y olmesartán, Interacciones medicamentosas)

Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e.g. rifampicin, St. (etiqueta de Amlodipino y valsartán, Interacciones medicamentosas)

CYP3A4/5 Inducers Co-administration of rifampin, a strong inducer of CYP3A4/5, reduced the plasma exposure of axitinib in healthy volunteers. (etiqueta de Axitinib, Interacciones medicamentosas)

Clinically Significant Interactions with Bexagliflozin Tablets UGT Enzyme Inducers Clinical Impact UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy [ see Clinical Pharmacology ( 12.3 )]. (etiqueta de Bexagliflozina, Interacciones medicamentosas)

Strong CYP3A4 inducers Double the recommended dosage and further adjust based on clinical response. (etiqueta de Brexpiprazol, Interacciones medicamentosas)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Examples: Macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g. ketoconazole), protease inhibitors (e.g., ritonavir) CYP3A4 Inducers Clinical Impact: The concomitant use of buprenorphine and CYP3A4 inducers can decrease the plasma concentration of buprenorphine [see Clinical Pharmacology (12.3) ] , potentially resulting in decreased efficacy… (etiqueta de Buprenorfina y naloxona, Interacciones medicamentosas)

Other inhibitors and inducers of CYP3A4: Substances that inhibit CYP3A4, such as ketoconazole or ritonavir, may inhibit buspirone metabolism and increase plasma concentrations of buspirone while substances that induce CYP3A4, such as dexamethasone or certain anticonvulsants (phenytoin, phenobarbital, carbamazepine), may increase the rate of buspirone metabolism. (etiqueta de Buspirona, Interacciones medicamentosas)

Table 7: Clinically Significant Drug Interactions with INVOKANA UGT Enzyme Inducers Clinical Impact: UGT enzyme inducers decrease canagliflozin exposure which may reduce the effectiveness of INVOKANA. (etiqueta de Canagliflozina, Interacciones medicamentosas)

• Strong inducer of CYP3A4 or CYP2C19: Consider dose increase of EPIDIOLEX. (etiqueta de Cannabidiol (con receta), Interacciones medicamentosas)

Inducers of Hepatic CYP Enzymes Rifampin : Rifampin is a potent CYP3A4 inducer and concomitant administration with caspofungin acetate for injection is expected to reduce the plasma concentrations of caspofungin acetate for injection. (etiqueta de Caspofungina, Interacciones medicamentosas)

Inducers of CYP3A4 and CYP3A5 Inducers of CYP3A4 and/or CYP3A5 may reduce plasma concentrations of clindamycin. (etiqueta de Clindamicina, Interacciones medicamentosas)

…several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well. (etiqueta de Clomipramina, Interacciones medicamentosas)

Advise females of reproductive potential to use an effective non-hormonal method of contraception, since LORBRENA can render hormonal contraceptives ineffective, during treatment with LORBRENA and for at least 6 months after the final dose. (etiqueta de Lorlatinib, Advertencias y precauciones)

Clinically Relevant Interactions Affecting DEXILANT When Coadministered with Other Drugs and Substances CYP2C19 or CYP3A4 Inducers Clinical Impact: Decreased exposure of dexlansoprazole when used concomitantly with strong inducers [see Clinical Pharmacology (12.3) ] . (etiqueta de Dexlansoprazol, Interacciones medicamentosas)

Advise females of reproductive potential to use an effective non-hormonal method of contraception, since LORBRENA can render hormonal contraceptives ineffective, during treatment with LORBRENA and for at least 6 months after the final dose. (etiqueta de Lorlatinib, Advertencias y precauciones)

Hepatic enzyme-inducing drugs (e.g., phenytoin, carbamazepine, phenobarbital, primidone, rifampin) can increase valproate clearance, while enzyme inhibitors (e.g., felbamate) can decrease valproate clearance. (etiqueta de Divalproato de sodio (valproato), Interacciones medicamentosas)

Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular… (etiqueta de Dofetilida, Interacciones medicamentosas)

Examples Glutethimide and phenobarbital Intervention If a patient initiates or discontinues therapy with an enzyme inducer, dose adjustment of doxercalciferol may be necessary. (etiqueta de Doxercalciferol, Interacciones medicamentosas)

Advise females of reproductive potential to use an effective non-hormonal method of contraception, since LORBRENA can render hormonal contraceptives ineffective, during treatment with LORBRENA and for at least 6 months after the final dose. (etiqueta de Lorlatinib, Advertencias y precauciones)

Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs. (etiqueta de Emtricitabina, rilpivirina y tenofovir, Interacciones medicamentosas)

CYP3A4 Inducers Pre-treatment with a CYP3A4 inducer prior to erlotinib decreased erlotinib exposure [see Clinical Pharmacology (12.3) ]. (etiqueta de Erlotinib, Interacciones medicamentosas)

Table 4: Clinically Relevant Interactions Affecting Esomeprazole When Co-Administered with Other Drugs CYP2C19 or CYP3A4 Inducers Clinical Impact: Decreased exposure of esomeprazole when used concomitantly with strong inducers [see Clinical Pharmacology (12.3) ]. (etiqueta de Esomeprazol, Interacciones medicamentosas)

While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations. (etiqueta de Estazolam, Advertencias)

Advise females of reproductive potential to use an effective non-hormonal method of contraception, since LORBRENA can render hormonal contraceptives ineffective, during treatment with LORBRENA and for at least 6 months after the final dose. (etiqueta de Lorlatinib, Advertencias y precauciones)

Advise females of reproductive potential to use an effective non-hormonal method of contraception, since LORBRENA can render hormonal contraceptives ineffective, during treatment with LORBRENA and for at least 6 months after the final dose. (etiqueta de Lorlatinib, Advertencias y precauciones)

Advise females of reproductive potential to use an effective non-hormonal method of contraception, since LORBRENA can render hormonal contraceptives ineffective, during treatment with LORBRENA and for at least 6 months after the final dose. (etiqueta de Lorlatinib, Advertencias y precauciones)

Advise females of reproductive potential to use an effective non-hormonal method of contraception, since LORBRENA can render hormonal contraceptives ineffective, during treatment with LORBRENA and for at least 6 months after the final dose. (etiqueta de Lorlatinib, Advertencias y precauciones)

Advise females of reproductive potential to use an effective non-hormonal method of contraception, since LORBRENA can render hormonal contraceptives ineffective, during treatment with LORBRENA and for at least 6 months after the final dose. (etiqueta de Lorlatinib, Advertencias y precauciones)

Advise females of reproductive potential to use an effective non-hormonal method of contraception, since LORBRENA can render hormonal contraceptives ineffective, during treatment with LORBRENA and for at least 6 months after the final dose. (etiqueta de Lorlatinib, Advertencias y precauciones)

Drugs that Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant use of rifampicin, a potent inducer of CYP3A4. (etiqueta de Eszopiclona, Interacciones medicamentosas)

Advise females of reproductive potential to use an effective non-hormonal method of contraception, since LORBRENA can render hormonal contraceptives ineffective, during treatment with LORBRENA and for at least 6 months after the final dose. (etiqueta de Lorlatinib, Advertencias y precauciones)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (etiqueta de Exemestano, Interacciones medicamentosas)

Phenobarbital Clinical Impact: Chronic administration of phenobarbital, a known enzyme inducer, may be associated with a decrease in the plasma half-life of fenoprofen. (etiqueta de Fenoprofeno, Interacciones medicamentosas)

CYP3A4 Inducers No dosing adjustments are recommended in the presence of CYP3A4 inducers, such as rifampin and carbamazepine. (etiqueta de Fesoterodina, Interacciones medicamentosas)

Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination. (etiqueta de Flecainida, Interacciones medicamentosas)

Advise females of reproductive potential to use an effective non-hormonal method of contraception, since LORBRENA can render hormonal contraceptives ineffective, during treatment with LORBRENA and for at least 6 months after the final dose. (etiqueta de Lorlatinib, Advertencias y precauciones)

• CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (etiqueta de Gefitinib, Interacciones medicamentosas)

…and its plasma concentrations can be significantly affected resulting in an increase in exposure Consider dose reduction [see Dosage and administration (2.7) ] Strong and moderate CYP3A4 inducers, e.g., rifampin, efavirenz Guanfacine is primarily metabolized by CYP3A4 and its plasma concentrations can be significantly affected resulting in a decrease in exposure… (etiqueta de Guanfacina, Interacciones medicamentosas)

Drugs that May Decrease Haloperidol Plasma Concentrations Coadministration of haloperidol with potent enzyme inducers of CYP3A4 may gradually decrease the plasma concentrations of haloperidol to such an extent that efficacy may be reduced. (etiqueta de Haloperidol, Interacciones medicamentosas)

Concomitant administration of inducers of CYP3A4 may lead to decreases in serum concentrations of ALKINDI SPRINKLE and increase the risk of adverse reactions, including adrenal crisis. (etiqueta de Hidrocortisona, Interacciones medicamentosas)

• CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (etiqueta de Ifosfamida, Interacciones medicamentosas)

The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration with hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary. (etiqueta de Imipramina, Interacciones medicamentosas)

Clinically Relevant Interactions Affecting PREVACID or PREVACID SoluTab When Coadministered with Other Drugs CYP2C19 OR CYP3A4 Inducers Clinical Impact: Decreased exposure of lansoprazole when used concomitantly with strong inducers [see Clinical Pharmacology (12.3) ] . (etiqueta de Lansoprazol, Interacciones medicamentosas)

Advise females of reproductive potential to use an effective non-hormonal method of contraception, since LORBRENA can render hormonal contraceptives ineffective, during treatment with LORBRENA and for at least 6 months after the final dose. (etiqueta de Lorlatinib, Advertencias y precauciones)

Advise females of reproductive potential to use an effective non-hormonal method of contraception, since LORBRENA can render hormonal contraceptives ineffective, during treatment with LORBRENA and for at least 6 months after the final dose. (etiqueta de Lorlatinib, Advertencias y precauciones)

Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with rifampin). (etiqueta de Linagliptina, Interacciones medicamentosas)

Inducers of P-glycoprotein or CYP3A4 Enzymes Clinical Impact Rifampin decreased linagliptin exposure, suggesting that the efficacy of linagliptin may be reduced when administered in combination with a strong P-gp or CYP3A4 inducer. (etiqueta de Linagliptina y metformina, Interacciones medicamentosas)

• If patients with severe renal impairment or ESRD receiving SELZENTRY (without concomitant CYP3A inducers or inhibitors) experience postural hypotension, the dose of SELZENTRY should be reduced from 300 mg twice daily to 150 mg twice daily. (etiqueta de Maraviroc, Advertencias y precauciones)

Advise females of reproductive potential to use an effective non-hormonal method of contraception, since LORBRENA can render hormonal contraceptives ineffective, during treatment with LORBRENA and for at least 6 months after the final dose. (etiqueta de Lorlatinib, Advertencias y precauciones)

Rifampin (Potent Inducer of CYP3A4) Coadministration of a single 500 mg oral dose of mefloquine and 600 mg of rifampin once daily for 7 days in 7 healthy Thai volunteers resulted in a decrease in the mean C max and AUC of mefloquine by 19% and 68%, respectively, and a decrease in the mean elimination half-life of mefloquine from 305 hours to 113 hours. (etiqueta de Mefloquina, Interacciones medicamentosas)

Advise females of reproductive potential to use an effective non-hormonal method of contraception, since LORBRENA can render hormonal contraceptives ineffective, during treatment with LORBRENA and for at least 6 months after the final dose. (etiqueta de Lorlatinib, Advertencias y precauciones)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (etiqueta de Memantina y donepezilo, Interacciones medicamentosas)

…agents (e.g., ketoconazole), protease inhibitors (e.g., ritonavir), fluconazole, fluvoxamine, some selective serotonin reuptake inhibitors (SSRIs) (e.g., sertraline, fluvoxamine) Inducers of CYP3A4, CYP2B6, CYP2C19, or CYP2C9 Clinical Impact: The concomitant use of methadone and CYP3A4, CYP2B6, CYP2C19, or CYP2C9 inducers can decrease the plasma concentration… (etiqueta de Metadona, Interacciones medicamentosas)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (etiqueta de Metilergometrina, Interacciones medicamentosas)

Hepatic Enzyme Inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin) : Drugs which induce cytochrome P450 3A4 enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (etiqueta de Metilprednisolona, Interacciones medicamentosas)

John's Wort, tramadol, tryptophan, buspirone Strong CYP3A Inducers Clinical Impact The concomitant use of strong CYP3A inducers with REMERON/REMERONSolTab decreases the plasma concentration of mirtazapine [see Clinical Pharmacology (12.3) ] . (etiqueta de Mirtazapina, Interacciones medicamentosas)

Table 4: Clinically Significant Interactions with Esomeprazole Magnesium - Affecting Co-Administered Drugs CYP2C19 or CYP3A4 Inducers Clinical Impact : Decreased exposure of esomeprazole when used concomitantly with strong inducers [see Clinical Pharmacology (12.3) ]. (etiqueta de Naproxeno y esomeprazol, Interacciones medicamentosas)

Possible Reduced Efficacy with Strong CYP3A4 Inducers Concomitant use of strong CYP3A4 inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifampin, St. (etiqueta de Nimodipino, Advertencias y precauciones)

Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (etiqueta de Nintedanib, Interacciones medicamentosas)

Advise females of reproductive potential to use an effective non-hormonal method of contraception, since LORBRENA can render hormonal contraceptives ineffective, during treatment with LORBRENA and for at least 6 months after the final dose. (etiqueta de Lorlatinib, Advertencias y precauciones)

Advise females of reproductive potential to use an effective non-hormonal method of contraception, since LORBRENA can render hormonal contraceptives ineffective, during treatment with LORBRENA and for at least 6 months after the final dose. (etiqueta de Lorlatinib, Advertencias y precauciones)

Advise females of reproductive potential to use an effective non-hormonal method of contraception, since LORBRENA can render hormonal contraceptives ineffective, during treatment with LORBRENA and for at least 6 months after the final dose. (etiqueta de Lorlatinib, Advertencias y precauciones)

Advise females of reproductive potential to use an effective non-hormonal method of contraception, since LORBRENA can render hormonal contraceptives ineffective, during treatment with LORBRENA and for at least 6 months after the final dose. (etiqueta de Lorlatinib, Advertencias y precauciones)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (etiqueta de Olmesartán, amlodipino e hidroclorotiazida, Interacciones medicamentosas)

Table 4: Clinically Relevant Interactions Affecting Omeprazole When Co-Administered with Other Drugs CYP2C19 or CYP3A4 Inducers Clinical Impact: Decreased exposure of omeprazole when used concomitantly with strong inducers [see Clinical Pharmacology ( 12.3 )] . (etiqueta de Omeprazol, Interacciones medicamentosas)

Table 6: Clinically Relevant Interactions Affecting Omeprazole when Co-Administered with Other Drugs CYP2C19 or CYP3A4 Inducers Clinical Impact: Decreased exposure of omeprazole when used concomitantly with strong inducers [see Clinical Pharmacology ( 12.3 )] . (etiqueta de Omeprazol y bicarbonato de sodio, Interacciones medicamentosas)

Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. (etiqueta de Ondansetrón, Interacciones medicamentosas)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (etiqueta de Pitolisant, Interacciones medicamentosas)

CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etiqueta de Prednisolona, Interacciones medicamentosas)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (etiqueta de Prednisona, Interacciones medicamentosas)

Advise females of reproductive potential to use an effective non-hormonal method of contraception, since LORBRENA can render hormonal contraceptives ineffective, during treatment with LORBRENA and for at least 6 months after the final dose. (etiqueta de Lorlatinib, Advertencias y precauciones)

• Concomitant use of strong CYP3A4 inducers: Increase quetiapine dose up to 5 fold when used in combination with a chronic treatment (more than 7-14 days) of potent CYP3A4 inducers (e.g., phenytoin, rifampin, St. (etiqueta de Quetiapina, Interacciones medicamentosas)

Antiepileptics (AEDs) (Carbamazepine, Phenobarbital, and Phenytoin) Carbamazepine, phenobarbital, and phenytoin are CYP3A4 inducers and may decrease quinine plasma concentrations if used concurrently with quinine sulfate. (etiqueta de Quinina, Interacciones medicamentosas)

Rifampin (strong CYP enzyme inducer): Decreases exposure to and effects of ramelteon. (etiqueta de Ramelteón, Interacciones medicamentosas)

CYP2C8 and CYP3A4 Inducers Intervention: Repaglinide tablets dose increases and increased frequency of glucose monitoring may be required when co‑administered. (etiqueta de Repaglinida, Interacciones medicamentosas)

Coadministration of EDURANT or EDURANT PED and drugs that induce CYP3A may result in decreased plasma concentrations of rilpivirine and loss of virologic response and possible resistance to rilpivirine or to the class of NNRTIs. (etiqueta de Rilpivirina, Interacciones medicamentosas)

Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone. (etiqueta de Risperidona, Interacciones medicamentosas)

Effects of Other AEDs on BANZEL Potent cytochrome P450 enzyme inducers, such as carbamazepine, phenytoin, primidone, and phenobarbital, appear to increase the clearance of BANZEL (see Table 6). (etiqueta de Rufinamida, Interacciones medicamentosas)

Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (etiqueta de Ruxolitinib, Interacciones medicamentosas)

Drugs that induce CYP3A4 (e.g., phenytoin, carbamazepine, nafcillin, phenobarbital, and rifampin) should be used with caution. (etiqueta de Selegilina, Interacciones medicamentosas)

• CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (etiqueta de Sunitinib, Interacciones medicamentosas)

Risk of Rejection with Strong CYP3A Inducers and Risk of Serious Adverse Reactions with Strong CYP3A Inhibitors The concomitant use of strong CYP3A inducers may increase the metabolism of tacrolimus, leading to lower whole blood trough concentrations and greater risk of rejection. (etiqueta de Tacrolimus, Advertencias y precauciones)

CYP3A4 inhibitors (e.g. ketoconazole, ritonavir) increase CIALIS exposure ( 2.7 , 5.10 , 7.2 ) requiring dose adjustment: CIALIS for use as needed: no more than 10 mg every 72 hours CIALIS for once daily use: dose not to exceed 2.5 mg CYP3A4 inducers (e.g. rifampin) decrease CIALIS exposure ( 7.2 ). (etiqueta de Tadalafilo, Interacciones medicamentosas)

Patients should be monitored for adequate clinical effect when amlodipine is co-administered with CYP3A4 inducers. (etiqueta de Telmisartán y amlodipino, Interacciones medicamentosas)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

Terbinafine clearance is increased 100% by rifampin, a CYP450 enzyme inducer, and decreased 33% by cimetidine, a CYP450 enzyme inhibitor. (etiqueta de Terbinafina, Interacciones medicamentosas)

Use of tiagabine HCl without enzyme-inducing antiepileptic drugs results in blood levels about twice those attained in the studies on which current dosing recommendations are based (see DOSAGE AND ADMINISTRATION ). (etiqueta de Tiagabina, Advertencias)

CYP3A4 inducers/inhibitors: Monitor for decreased tinidazole effect or increased adverse reactions ( 7.2 ) (etiqueta de Tinidazol, Interacciones medicamentosas)

DRUG INTERACTIONS Hepatic microsomal enzyme inducing agents, such as carbamazepine, were found to significantly increase the clearance of thiothixene. (etiqueta de Tiotixeno, Interacciones medicamentosas)

…exposure to tofacitinib Intervention Dosage modification of XELJANZ/XELJANZ XR is recommended [see Dosage and Administration (2) , Clinical Pharmacology, Figure 3 (12.3) ] Strong CYP3A4 Inducers (e.g., rifampin) Clinical Impact Decreased exposure to tofacitinib and may result in loss of or reduced clinical response Intervention Concomitant use with XELJANZ/XELJANZ… (etiqueta de Tofacitinib, Interacciones medicamentosas)

CYP3A4 Inducers: Increase in RALDESY dosage may be necessary ( 2.5 , 7 ). (etiqueta de Trazodona, Interacciones medicamentosas)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (etiqueta de Treprostinilo, Advertencias y precauciones)

Hepatic enzyme inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (etiqueta de Triamcinolona, Interacciones medicamentosas)

Strong Inducers of CYP 3A Clinical implication Coadministration of triazolam with strong inducers of CYP3A4 can significantly decrease the plasma concentration of triazolam and may decrease effectiveness of triazolam. (etiqueta de Triazolam, Interacciones medicamentosas)

CYP3A4 Inducers: Consider increasing VIIBRYD dosage by 2-fold, up to 80 mg once-daily over 1 to 2 weeks when used concomitantly with strong CYP3A4 inducers for greater than 14 days ( 2.4 , 7 ). (etiqueta de Vilazodona, Interacciones medicamentosas)

Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon C max and AUC by approximately 80%. (etiqueta de Zaleplón, Interacciones medicamentosas)

Pharmacokinetic Interactions Carbamazepine Carbamazepine is an inducer of CYP3A4; administration of 200 mg twice daily for 21 days resulted in a decrease of approximately 35% in the AUC of ziprasidone. (etiqueta de Ziprasidona, Interacciones medicamentosas)

CYP3A4 Inducers If co-administration with a potent CYP3A4 inducer is necessary, the patient should be closely monitored and the dose of ZONISAMIDE and other drugs that CYP3A4 substrates may need to be adjusted [see Clinical Pharmacology ( 12.3 )] . (etiqueta de Zonisamida, Interacciones medicamentosas)

The selective serotonin reuptake inhibitors sertraline (weak CYP3A4 inducer) and fluoxetine (CYP2D6 inhibitor), and the anti-epileptic drug felbamate (CYP2C19 inhibitor and CYP3A4 inducer) do not affect the pharmacokinetics of clonazepam. (etiqueta de Clonazepam, Interacciones medicamentosas)

• PGP Inducers/Inhibitors: Drugs that induce or inhibit PGP have the potential to alter digoxin pharmacokinetics. (etiqueta de Digoxina, Interacciones medicamentosas)

Drug Interactions If phenytoin or other hepatic enzyme inducers are taken concurrently with Norpace or Norpace CR, lower plasma levels of disopyramide may occur. (etiqueta de Disopiramida, Interacciones medicamentosas)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (etiqueta de Docetaxel, Interacciones medicamentosas)

TAF is not an inhibitor or inducer of CYP3A in vivo . (etiqueta de Emtricitabina y tenofovir, Interacciones medicamentosas)

Effects of Other Drugs on HALAVEN No drug-drug interactions are expected with CYP3A4 inhibitors, CYP3A4 inducers or P-glycoprotein (P-gp) inhibitors. (etiqueta de Eribulina, Interacciones medicamentosas)

Potential for Glycerol Phenylbutyrate to Affect Other Drugs Drugs with narrow therapeutic index that are substrates of CYP3A4 Glycerol phenylbutyrate is a weak inducer of CYP3A4 in humans. (etiqueta de Fenilbutirato de glicerol, Interacciones medicamentosas)

When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with mexiletine, lowered mexiletine plasma levels have been reported. (etiqueta de Mexiletina, Interacciones medicamentosas)

CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (etiqueta de Rifaximina, Interacciones medicamentosas)

Strong CYP3A inducers: Strong inducers of CYP3A (for example, rifampin, phenytoin, carbamazepine, phenobarbital or St. (etiqueta de Riociguat, Interacciones medicamentosas)

Concurrent use of strong CYP3A inducers (e.g., St. (etiqueta de Vincristina, Interacciones medicamentosas)

Drugs Having No Clinically Important Interactions with SAPHRIS No dosage adjustment of SAPHRIS is necessary when administered concomitantly with paroxetine (see Table 12 in Drug Interactions ( 7.1 ) for paroxetine dosage adjustment), imipramine, cimetidine, valproate, lithium, or a CYP3A4 inducer (e.g., carbamazepine, phenytoin, rifampin). (etiqueta de Asenapina, Interacciones medicamentosas)

CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. (etiqueta de Micafungina, Interacciones medicamentosas)

…adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology (12.3) ]. (etiqueta de Montelukast, Interacciones medicamentosas)